Market Overview

bluebird bio Announces Presentation at Cooley's Anemia Foundation Symposium


bluebird bio, Inc. (Nasdaq: BLUE) announced that Marina Cavazzana, M.D.,
Ph.D., professor of hematology and director of the Department of
Biotherapy at Hospital Necker, University Paris Descartes and lead
investigator for the HGB-205 clinical study, presented a review of the
clinical study experience with lentiviral-based gene therapies for
beta-thalassemia at the 10th Annual Cooley's Anemia
Foundation Symposium in Chicago today.

Professor Cavazzana summarized results from HGB-205, an ongoing clinical
study using LentiGlobin® BB305 for the treatment of
beta-thalassemia major and severe sickle cell disease, which were
presented earlier this year at the Annual Congress of the European
Hematology Association. She also provided an update on subject 1003, a
patient with

See full press release

Posted-In: News Press Releases


Related Articles (BLUE)

View Comments and Join the Discussion!